Enspryng
Named-patient access overview. Enspryng is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Enspryng (satralizumab-mwge) is Roche's IL-6 receptor-targeted monoclonal antibody for neuromyelitis optica spectrum disorder in adults who test positive for anti-aquaporin-4 antibodies. It received FDA approval in August 2020 and is one of three approved NMOSD therapies (alongside eculizumab and inebilizumab). For Saudi Arabia patients with AQP4-positive NMOSD whose treating neurologist has recommended satralizumab, this page describes the SFDA Personal Importation Program pathway.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Enspryng
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Enspryng is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Enspryng in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Enspryng
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.